Alpha-antitrypsin - PPL Therapeutics
Alternative Names: AAT - PPL Therapeutics; Alpha-1 proteinase inhibitor - PPL Therapeutics; Alpha-1-antitrypsin - PPL Therapeutics; rAAT - PPL Therapeutics; recAAT - PPL Therapeutics; Recombinant AAT; TgAAT - PPL TherapeuticsLatest Information Update: 25 Sep 2021
Price :
$50 *
At a glance
- Originator PPL Therapeutics PLC
- Developer Bayer; PPL Therapeutics PLC
- Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Antiallergics; Antihyperglycaemics; Blood proteins; Enzymes; Secretory proteinase inhibitory proteins; Serpins
- Mechanism of Action Leucocyte elastase inhibitors; Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Adult respiratory distress syndrome; Alpha 1-antitrypsin deficiency; Cystic fibrosis
Most Recent Events
- 10 Jul 2003 Suspended - Clinical-Phase-Unknown for Alpha 1-antitrypsin deficiency in United Kingdom (IV)
- 10 Jul 2003 Suspended - Phase-II for Alpha 1-antitrypsin deficiency in United Kingdom (Inhalation)
- 10 Jul 2003 Suspended - Phase-II for Cystic fibrosis in United Kingdom (Inhalation)